Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of guselkumab versus placebo and adalimumab in moderate to severe plaque psoriasis with randomized withdrawal and retreatment
2014-000720-18Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in plaque psoriasis and psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: IGA 0/1 response at Week 16 and PASI 90 response at Week 16. Started Aug 2014; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2014-000720-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000720-18.